Anakinra(ann ack’ in rah)
Kineret
PREGNANCY CATEGORY B
Drug Classes
Antiarthritic
Interleukin-1 receptor antagonist
Therapeutic Actions
A recombinant human interleukin-1 receptor antagonist; blocks the activity of interleukin-1 that is elevated in response to inflammatory and immune stimulation and is responsible for the degradation of cartilage due to the rapid loss of proteoglycans in rheumatoid arthritis.
Indications
Reduction of the signs and symptoms and slowing of progression of moderately to severely active rheumatoid arthritis in patients 18 yr and older who have failed on one or more disease-modifying anti-rheumatic drugs (methotrexate, sulfasalazine, hydroxychloroquine, gold, penicillamine, leflunomide, azathioprine); used alone or with disease-modifying antirheumatic drugs other than tumor necrosis factor blockers
Unlabeled use: Juvenile idiopathic arthritis
Contraindications and Cautions
Contraindicated with allergy to anakinra or proteins produced by Escherichia coli.
Use cautiously with immunosuppression, active infection, pregnancy, lactation, renal impairment.
Available Forms
Prefilled glass syringes—100 mg/0.67 mL
Dosages
Adults
100 mg/day subcutaneously at approximately the same time each day.
Pediatric patients
Safety and efficacy not established.
Patients with renal impairment
For patients with end-stage renal disease or CrCl less than 30 mL/min, 100 mg every other day.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
